Clinical trial
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive…
NCT00435578 · Threshold Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00435578 |
|---|---|
| Title | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma |
| Official title | An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma |
| Lead sponsor | Threshold Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell Lung |
| Intervention type | Drug |
| Interventions | Glufosfamide |
| Enrollment | 50 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 15, 2007 |
| Last update posted | Apr 30, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: